An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy.

Fiche publication

Date publication

juin 2026

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Dr LADOIRE Sylvain , Mme TRUNTZER Caroline

Tous les auteurs :
Ilie SM, Lecuelle J, Ghiringhelli F, Truntzer C, Ladoire S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42382385

Résumé

Human endogenous retroviruses (HERVs) are single-stranded RNA viruses that have integrated into the human germline, and whose sequences represent approximately 8% of the human genome. In cancer cells, certain HERV sequences can be re-expressed, thereby promoting an innate and adaptive immune response, particularly through the induction of an interferon response in tumors, known as "viral mimicry". We sought to elucidate the links between HERV expression and tumor immunogenicity in different biological subtypes of early breast cancer (eBC).